Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in Q4, the analyst tells investors in a research note. The firm says AbbVie’s 2025 expected combined Skyrizi and Rinvoq revenues of $24B exceeds consensus and reaffirms the duo’s strength and ability in sunsetting Humira erosion concerns.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: